title: Reply to DiNubile.
authors.affiliation: Department of Medicine, Division of Infectious Disease, Duke University Medical Center, Durham, North Carolina.
authors.forename: G Ralph
authors.initials: GR
authors.lastname: Corey
authors.affiliation: Division of Infectious Diseases and Geographic Medicine, Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts.
authors.forename: Helen W
authors.initials: HW
authors.lastname: Boucher
authors.affiliation: Department of Medicine, Section of Infectious Diseases, Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno" (CEMIC), Ciudad Autónoma de Buenos Aires, Argentina.
authors.forename: Martin E
authors.initials: ME
authors.lastname: Stryjewski
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D016470:Bacteremia / Q000188:drug therapy* / Q000382:microbiology*; D002437:Cefazolin / Q000627:therapeutic use*; D005260:Female; D006020:Glycopeptides / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D016106:Methicillin Resistance; D017192:Skin Diseases, Bacterial / Q000188:drug therapy*; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology*; D014640:Vancomycin / Q000008:administration & dosage* / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D014640:Vancomycin; D002437:Cefazolin